An Integrated Investigation of Vascular Cognitive Impairment in Population Based Studies Across Europe



Blossom CM Stephan¹, Fiona E Matthews², Kay-Tee Khaw³, Carole Dufouil⁴, Shabina Hyatt¹, Carol Brayne¹

1. Department of Public Health and Primary Care, The University of Cambridge, CB2 OSR, UK; 2. MRC Biostatistics Unit, The University of Cambridge, CB2 OSR, UK; 3. Department of Clinical Gerontology, The University of Cambridge, Cambridge, CB2 0SR, UK; 4. Institut National de la Santé et de la Recherche Médicale Unit 360, Epidemiological research in neurology and psychopathology, Paris, France.

Background

- The incidence and prevalence of cognitive decline and dementia is expected to increase with population ageing.
- Ageing is associated with changes in all components of the vascular system and increased risk of cardiovascular and cerebrovascular disease.
- Vascular factors (e.g., poor diet and smoking) and conditions (e.g., stroke, hypertension and obesity) are risks for cognitive decline and dementia.
- Cognitive decline attributable to vascular factors has been termed "Vascular Cognitive Impairment" (VCI)¹.
- VCI encompasses all individuals showing cognitive decline caused by or associated with vascular factors or conditions.
- VCI ranges in severity from Vascular Cognitive Impairment No Dementia (VCIND) to dementia (Figure 1).
- Whether VCIND identifies individuals at risk of developing dementia secondary to vascular disease is not known.
- A more complete understanding of the relationship between vascular disease, cognitive decline and dementia will have important implications in identifying elderly vulnerable population subgroups for treatment and prevention.




Figure 1. Model of cognitive decline and dementia risk associated with vascular ageing.

PROJECT AIMS

- Explore the relationships between vascular factors, cognitive decline and dementia.
- Determine vascular markers that are sensitive and specific in identifying those individuals who are likely to progress to dementia as a consequence of co-morbid vascular disease/factors.

Research Questions

- 1. Can VCIND be defined?
- 2. What is the population prevalence of VCIND?
- 3. What is the role of vascular factors and conditions in cognitive decline and its progression to dementia?
- 4. Do trajectories of change depend on source of information (i.e., biological, neural, molecular, nutritional, clinical), baseline severity and/or aggregation of vascular disease/factors?
- 5. Do demographic variables moderate the effect of vascular disease on cognitive decline and progression to dementia?
- 6. What are the necessary diagnostic requirements for accurate discrimination of those persons at risk of progressing to dementia secondary to vascular disease/factors?

Cross Study Collaboration

- Harmonisation of three data resources (Figure 2) including:
 - EClipSE Determine the prevalence and severity of neuropathological lesions across the spectrum of age associated changes (i.e., normal, VCIND, dementia).
 - The 3C-Study Examine tissue integrity using MRI to identify the extent of changes that render an individual susceptible to dementia in response to vascular disease/factors.
 - EPIC-Norfolk Investigate lifestyle/disease interactions to identify modifiable risks that initiate disease and contribute to its progression.

EClipSE

- Synthesis of 3 European populationbased clinico-pathological studies with longitudinal follow-up of cognition and health.
- Contributing studies include:
 - The Medical Research Council Cognitive function and Ageing Study (MRC CFAS).
 - The Cambridge City over 75 Cohort (CC75C).
 - The Vantaa 85+ Study.
- n=1,024.

Data Resources:

Core: Neuropathology Additional: Sociodemographic, medical, genetics, cognitive function, depression and disability.

Figure 2. Data Resources.

EPIC-Norfolk

Data Resources

- Part of a nine country, half-million cohort collaboration investigating the relationships between diet, cancer and chronic disease.
- 30,446 men and women aged 40-79 years from general practice age-sex registers in Norfolk, UK.

Data Resources:

Core: Lifestyle/physical activity, diet (food frequency diaries), reproductive history, medical and family history, height, weight, waist and hip measures and blood samples. Additional: Heel ultrasound (estimates of fat percentage), eye examination and measures of physical and cognitive functioning.

The 3C-Study

- Longitudinal population-based cohort study of cognition and vascular related disease.
- 9,693 individuals aged 65 years and over recruited from the electoral rolls of three French cities (Bordeaux, Dijon, Montpellier).

Data Resources:


Core: Blood pressure, ultrasound of the carotid arteries, measurement of biological parameters (e.g., glycemia, total cholesterol levels, triglycerides and creatinemia), and cognitive function.

Additional: Magnetic resonance imaging (MRI) (n=3,442)

Defining Cognitive Decline

- Cognitive decline defined using definitions of Mild Cognitive Impairment (MCI) including:
 - Age Related Cognitive Decline (ARCD)².
 - Mini Mental State Examination derived MCI (MMSE_{MCI})³.
 - Revised Mayo Clinic MCI (R-MCI)⁴.
- Individuals will be classified into three dementia risk groups including: low, medium and high risk.
- Sub-classifications derived distinguishing impairment with (i.e., VCIND) and without (i.e., MCI) comorbid risk factors (Table 1).

Table 1. Risk Factors for Vascular Cognitive Impairment (VCI).



Methods

- Map MCI and VCIND retrospectively in each study.
- Datasets will be harmonised to allow the different study methodologies to be evaluated.

Analysis Plan

- Primary outcome measure: Transition including stability, remission or progression to dementia.
- Secondary outcome measures: Mortality and dependency.
- Potential covariates include age, gender, genotype, site, start and follow-up date and demographic variables.
- Analysis will be completed in two main stages:
 - 1. Incidence and prevalence of MCI and VCIND.
 - 2. Longitudinal modelling of the evolution of disease and the extent to which different vascular factors influence rates of disease progression.

Preliminary Results - Prevalence of Co-morbid Risk Factors Across Dementia Risk Groups Defined Using R-MCI

- Variable prevalence of different risk factors in the nondemented groups as shown in Figure 3.
- Higher prevalence of depression, stroke, epilepsy and Parkinson's Disease in individuals with dementia (Figure 3).




Figure 3. Prevalence of each vascular factor: (a) population prevalence >10%; and, (b) population prevalence <10%.

Preliminary Results - Dementia Risk (Multinominal Logistic Regression)

- For all MCI definitions, individuals with depression, diabetes, epilepsy, Parkinson's Disease and history of stroke were at an increased risk of dementia.
- All associations remained significant after covariate adjustment, with the exception of diabetes.
- Risk factor profiles varied across the different risk levels (no dementia) and were not consistent with those observed for dementia.
- Individuals with depression, asthma, history of head injury and stroke were found to be at increased risk of cognitive decline (no dementia).
- Associations depended on definition and covariate adjustment.

WHY DO THIS STUDY?

- Cognitive impairment commonly accompanies clinical syndromes associated with vascular factors/disease.
- There is substantial controversy about the frequency of cognitive impairment attributable to vascular factors/disease.
- Risk identification offers promise for the identification and development of neuroprotective strategies.

References

- 1. Bowler JV, Hachinski V. Vascular cognitive impairment: a new approach to vascular dementia. Baillieres Clinical Neurology 1995;4: 357-376.
- 2. Diagnostic and Statistical Manual of Mental Disorders, Text Revision, 4th Ed. Washington, DC: American Psychiatric Association, 2000.
- 3. Folstein M, Folstein S, McHugh PR. Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research 1975;12: 189-198.
- 4. Petersen RC, Morris JC. Mild Cognitive Impairment as a Clinical Entity and Treatment Target. Archives of Neurology 2005;62: 1160-1163.



Acknowledgements: